• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Melanoma vaccine forges ahead


Z?rich - Among skin cancer vaccines, Canvaxin (CancerVax Corp.) stands alone for reasons that include its unique profile of immunopotent antigens and its evidence for potential efficacy in extensive phase 2 testing. Perhaps more importantly, Canvaxin is currently the only skin cancer vaccine that's in large-scale phase 3 randomized postsurgical adjuvant trials for patients with stage 3 and 4 melanoma. These studies, if positive, will provide the necessary efficacy and safety data to support marketing approval.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.